Our publications
The following are examples of our team's hundreds of academic publications:
Journal articles
Churchill NW, Spring R, Grady C, Cimprich B, Askren MK, Reuter-Lorenz PA, Jung MS, Peltier S, Strother SC, Berman MG. The suppression of scale-free fMRI brain dynamics across three different sources of effort: aging, task novelty and task difficulty. Sci Rep. 2016; 6:30895.
Matthews DC, Lukic AS, Andrews RD, Marendic B, Brewer J, Rissmanb RA, Mosconic L, Strother SC, Wernick MN, Mobley WC, Nessf S, Schmidt ME, Rafii MS. Dissociation of Down syndrome and Alzheimer’s disease effects with imaging. Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2 (2016) 69-81
Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, Margolin R, Landau S, Foster NL, Mason NS, De Santi S, Suhy J, Koeppe RA, Jagust W; Alzheimer's Disease Neuroimaging Initiative. The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data. Alzheimers Dement. 2015;11(9):1050-68.
Matthews DC, Davies M, Murray J, Tsui W, Yi L, Lukic AS, Andrews RD, deLeon MJ, Mosconi L. Physical activity, Diet and biomarker-assessed risk of Alzheimer’s disease: a multi-modality brain imaging study. Advances in Molecular Imaging. 2014; 4(4): 43-57.
Shah RC, Matthews DC, Andrews RD, Capuano AW, Fleischman DA, VanderLugt JT, Colca JR1. An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease. Curr Alzheimer Res. 2014;11(6):564-73.
Fleischman DA, Leurgans S, Arfanakis K, Arvanitakis Z, Barnes LL, Boyle PA, Han SD, Bennett DA. Gray-matter macrostructure in cognitively healthy older persons: associations with age and cognition. Brain Struct Funct. 2014 Nov;219(6):2029-49. doi: 10.1007/s00429-013-0622-7.
Mosconi L, Andrews RD, Matthews DC. Comparing brain amyloid deposition, glucose metabolism, and atrophy in mild cognitive impairment with and without a family history of dementia. J Alzheimers Dis. 2013;35(3):509-24.
Yourganov G, Chen X, Lukic AS, Grady CL, Small SL, Wernick MN, Strother SC. Dimensionality estimation for optimal detection of functional networks in BOLD fMRI data. Neuroimage, 2011; 56(2):531-43
Schmidt ME, Andrews RD, van der Ark P et al. Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects. Psychopharmacology (Berl) 2010; 208:109-119.
Lukic AS, Wernick MN, Tzikas DG, Chen X, Likas A, Galatsanos NP, Yang Y, Zhao F, Strother SC. Bayesian kernel methods for analysis of functional neuroimages. IEEE Trans Med Imaging. 2007 Dec;26(12):1613-24.
Lukic AS, Wernick MN, Yang Y, Hansen LK, Arfanakis K, Strother SC. Effect of spatial alignment transformations in PCA and ICA of functional neuroimages. IEEE Trans Med Imaging. 2007 Aug;26(8):1058-68.
Strother SC, Anderson J, Hansen LK, Kjems U, Kustra R, Siditis J, Frutiger S, Muley S, LaConte S, Rottenberg D. The quantitative evaluation of functional neuroimaging experiments: The NPAIRS data analysis framework. Neuroimage 2002; 15:747-771.
Lukic AS, Wernick MN, Strother SC. An evaluation of methods for detecting brain activations from functional neuroimages. Artif Intell Med. 2002 May;25(1):69-88.
Books and book chapters
Miles N. Wernick and John N. Aarsvold, Emission Tomography: The Fundamentals of PET and SPECT, Elsevier 2004
Schmidt ME, Matthews D, Andrews R, Mosconi L. Positron Emission Tomography in Alzheimer Disease. Chapter 5, Translational Neuroimaging, Tools for CNS Drug Discovery, Development and Treatment. McArthur RA, ed., Academic Press, 2013; 131-174.
Schmidt ME, Matthews DC, Andrews RA, Mosconi L. PET imaging in Alzheimer’s Disease. Book chapter in Brain imaging: Translational tools for CNS drug discovery, development and treatment. McArthur R, ed. Elsevier, 2012.
Strother SC, Oder A, Spring R, Grady C. The NPAIRS Computational Statistics Framework for Data Analysis in Neuroimaging. Proc. 19th Int. Conf. on Computational Statistics: Refereed Keynote, Invited and Contributed Papers, Lechevallier, Yves; Saporta, Gilbert (Eds.), 2010; 111-120, Physica-Verlag, Berlin.
Conference abstracts
Matthews DC, Lukic AS, Andrews RD, Schmidt ME, Wernick MN, Strother SC, for the Alzheimer’s Disease Neuroimaging Initiative. Measurement of amyloid burden using an early frame amyloid PET multivariate classifier. Alzheimer’s Association International Conference, 2016
Matthews DC, Lukic AS, Andrews RD, Wernick MN, Strother SC, PhD, Schmidt ME for the Alzheimer’s Disease Neuroimaging Initiative. Combining Neurodegenerative Characterization with Amyloid Burden Measurement Using an Early Frame Amyloid PET Multivariate Classifier. Alzheimer’s Association International Conference, 2016
Matthews DC, Andrews RD, Lukic AS, Yokoyama M, Marendic B, Wernick MN, Strother SC, Relationships between tau burden measured using AV1451 PET, regional cerebral glucose metabolism, and cognitive status. Alzheimer’s Association International Conference, 2016
Matthews DC, Lukic AS, Andrews RD, Marendic B, Brewer J, Rissmanb RA, Mosconic L, Strother SC, Wernick MN, Mobley WC, Nessf S, Schmidt ME, Rafii MS. Differentiating the Effects of Down Syndrome and Alzheimer’s Disease upon Neuronal Function and Brain Volume. Clinical Trials in Alzheimer’s Disease conference, 201
Churchill NW, Spring R, Afshin-Pour B, Dong F, Strother SC. An Automated, Adaptive Framework for Optimizing Preprocessing Pipelines in Task-Based Functional MRI. PLoS One. 2015;10(12):e0145594.
Matthews DC, MS MM, Andrews RD, MS, Marendic B, PhD, Yokoyama M PhD, Lukic AS, PhD for the Alzheimer’s Disease Neuroimaging Initiative. Neurodegenerative Variability Among Amyloid Positive MCI Patients – Implications for Clinical Trials and Clinical Care. Alzheimer’s Association International Conference, 2015
Matthews DC, Lukic AS, Andrews RD, Streffer J, Liu E, Van Neuten L, Wernick M, Strother S, Schmidt ME, ADNI. Detection of an FDG AD signature in early MCI and cognitively normal subjects and its potential for clinical trial enrichment. Clinical Trials in Alzheimer’s Disease conference, 2014
Matthews DC, Marendic B, Andrews RD, Lukic AS, Einstein S, Liu E, Margolin RA, Schmidt ME, ADNI. Longitudinal amyloid measurement for clinical trials: A new approach to overcome variability. Human Amyloid Imaging Meeting, 2014.
Schmidt ME et al. Preliminary analysis of baseline FDG PET in PET substudies of Phase 3 i.v. bapineuzumab trials in mild to moderate AD: Patterns and severity of regional brain hypometabolism and relationship to fibrillary amyloid burden measured by 11C-PiB PET and clinical outcomes. Clinical Trials in Alzheimer’s Disease conference, 2013.
Mosconi L, Andrews RD, Lukic AS, Wernick MN, Strother SC, Liu E, Margolin R, Schmidt ME, Matthews DC on behalf of A. A multivariate FDG PET classifier metric improves prediction of cognitive change in Normals, MCI and AD patients. Abstract, oral presentation. Clinical Trials in Alzheimer’s Disease Conference, 2013.
Strother SC, Matthews D, Lukic A, Andrews R, Wernick MN, and the Alzheimer's Disease Neuroimaging Initiative (ADNI). Superior Performance of a Multi-Stage PET Classifier for the Alzheimer’s Disease Cascade. Baycrest MCI Conference, 2012.
Matthews DC, Mosconi L, Andrews RD, Margolin R, Liu E, Schmidt ME and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Reference region quality control as a critical aspect of amyloid measurement using PET. Human Amyloid Imaging Meeting, 2012.
Mosconi L, Andrews RD, Liu E, Schmidt ME, Matthews DC and the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Characterization and maximization of longitudinal PiB changes by accurate sampling and quantitation for clinical trials. Human Amyloid Imaging Meeting, 2012.
Strother SC, Matthews D, Lukic A, Andrews R, Wernick M, and the Alzheimer's Disease Neuroimaging Initiative (ADNI). Superior Performance of a Multi-Stage PET Classifier for the Alzheimer’s Disease Cascade. Human Brain Mapping Conference, 2011.
Matthews D, Andrews R, Diehl-Schmid J, Grafman J, Mosconi L, deLeon MJ and the Alzheimer’s Disease Neuroimaging Initiative. Regional cerebral glucose metabolism provides a sensitive and specific marker of Alzheimer’s Disease, Frontotemporal Dementia and Mild Cognitive Impairment, and correlates with cerebrospinal fluid Abeta42 level decline in cognitively normal subjects. International Conference on Alzheimer’s Disease, 2010.
Matthews D, Mosconi M, Andrews R, Rickert K, Tsui WH, Li Yi, de Leon M, and the Alzheimer’s Disease Neuroimaging Initiative. Hippocampal Glucose Metabolism Predicts Cognitive Decline and Correlates to Disease Progression in the ADNI Population. International Conference on Alzheimer's Disease, 2009.
Matthews D, Mosconi M, Andrews R, Rickert K, Tsui WH, Li Yi, Mistur R, de Leon M, and the Alzheimer’s Disease Neuroimaging Initiative. Regional cerebral glucose metabolism at baseline predicts symptom onset in normal ADNI subjects and correlates to disease progression. ADNI Investigators Meeting, April, 2009.
Matthews D, Mosconi M, Andrews R, Brown T, Rickert K, Tsui WH, Li Yi, Mistur R, de Leon M, and the Alzheimer’s Disease Neuroimaging Initiative. Combining amyloid imaging and measurement of regional cerebral glucose metabolism to evaluate dementia state and progression. Human Amyloid Imaging Meeting, 2009.
Matthews D, Andrews R, Rickert K, Mosconi L, Tsui W, Li Y, deLeon MJ, and the Alzheimer’s Disease Neuroimaging Initiative. Regional cerebral glucose metabolism predicts decline in MCI subjects and provides a sensitive biomarker of disease progression. Clinical Trials in Alzheimer’s Disease conference, 2009.
